Shanghai Junshi Bio reported toripalimab, the company's anti-PD-1 drug, was effective as a first-line treatment for nasopharyngeal carcinoma. In a China Phase III trial, a combination of toripalimab plus chemotherapy met its pre-specified endpoint of progression-free survival in an interim analysis. In 2018, toripalimab was approved in China as a second-line therapy for melanoma, the first China-developed anti-PD-1 mAb authorized for launch. Earlier this year, Coherus Bio entered a $1.1 billion agreement with Junshi for US-Canada rights to toripalimab. More details.... Stock Symbols: (HK: 1877; SHA: 688180) (NSDQ: CHRS) Share this with colleagues: // //